Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation

JACC: Heart Failure

Volumn 5, Issue 1, 2017, Pages 44-52

  Pandey, Ambarish ^a   Kim, Sunghee ^b   Moore, Curtiss ^a   Thomas, Laine ^b   Gersh, Bernard ^c   Allen, Larry A ^d   Kowey, Peter R ^e   Mahaffey, Kenneth W ^f   Hylek, Elaine ^g   Peterson, Eric D ^b   Piccini, Jonathan P ^b   Fonarow, Gregg C ^h  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Mayo Clinic College of Medicine   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UCLA MEDICAL CENTER   (United States)

Author keywords

atrial fibrillation; heart failure; heart failure with preserved ejection fraction; outcomes

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANTIARRHYTHMIC AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRONEDARONE; FLECAINIDE; MINERALOCORTICOID ANTAGONIST; PROPAFENONE; SOTALOL;

AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVERSION; CATHETER ABLATION; CHADS2 SCORE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE REGISTRY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; HEALTH CARE UTILIZATION; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SINUS RHYTHM; VALVULAR HEART DISEASE; COMPLICATION; HEART STROKE VOLUME; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MALE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STROKE VOLUME;

EID: 85007610617     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.09.016     Document Type: Article

References (31)

1. 1 Go, A.S., Hylek, E.M., Phillips, K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285 (2001), 2370–2375.
2. 2 Go, A.S., Mozaffarian, D., Roger, V.L., et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129 (2014), e28–e292.
3. 3 Kim, M.H., Johnston, S.S., Chu, B.C., et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 4 (2011), 313–320.
4. 4 Piccini, J.P., Hammill, B.G., Sinner, M.F., et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993–2007. Circ Cardiovasc Qual Outcomes 5 (2012), 85–93.
5. 5 Miyasaka, Y., Barnes, M.E., Gersh, B.J., et al. Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur Heart J 27 (2006), 936–941.
6. 6 Santhanakrishnan, R., Wang, N., Larson, M.G., et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133 (2016), 484–492.
7. 7 Schnabel, R.B., Rienstra, M., Sullivan, L.M., et al. Risk assessment for incident heart failure in individuals with atrial fibrillation. Eur J Heart Fail 15 (2013), 843–849.
8. 8 Wang, T.J., Larson, M.G., Levy, D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107 (2003), 2920–2925.
9. 9 Thihalolipavan, S., Morin, D.P., Atrial fibrillation and heart failure: update 2015. Prog Cardiovasc Dis 58 (2015), 126–135.
10. 10 Potpara, T.S., Polovina, M.M., Licina, M.M., Marinkovic, J.M., Lip, G.Y., Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study. Eur J Heart Fail 15 (2013), 415–424.
11. 11 Piccini, J.P., Fraulo, E.S., Ansell, J.E., et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 162 (2011), 606–612.e1.
12. 12 Holmqvist, F., Kim, S., Steinberg, B.A., et al. Heart rate is associated with progression of atrial fibrillation, independent of rhythm. Heart 101 (2015), 894–899.
13. 13 Steinberg, B.A., Kim, S., Thomas, L., et al. Increased heart rate is associated with higher mortality in patients with atrial fibrillation (AF): results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). J Am Heart Assoc, 4, 2015, e002031.
14. 14 Holmqvist, F., Guan, N., Zhu, Z., et al. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 169 (2015), 647–654.e2.
15. 15 Avery, C.L., Loehr, L.R., Baggett, C., et al. The population burden of heart failure attributable to modifiable risk factors: the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol 60 (2012), 1640–1646.
16. 16 Gerber, Y., Weston, S.A., Redfield, M.M., et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 175 (2015), 996–1004.
17. 17 Suzuki, S., Sagara, K., Otsuka, T., et al. A new scoring system for evaluating the risk of heart failure events in Japanese patients with atrial fibrillation. Am J Cardiol 110 (2012), 678–682.
18. 18 Kannel, W.B., Wolf, P.A., Benjamin, E., Levy, D., Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82 (1998), 2N–9N.
19. 19 Zile, M.R., Gottdiener, J.S., Hetzel, S.J., et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 124 (2011), 2491–2501.
20. 20 Everett, T.H., Olgin, J.E., Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 4 (2007), S24–S27.
21. 21 Tsang, T.S., Gersh, B.J., Appleton, C.P., et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40 (2002), 1636–1644.
22. 22 Miller, J.D., Aronis, K.N., Chrispin, J., et al. Obesity, exercise, obstructive sleep apnea, and modifiable atherosclerotic cardiovascular disease risk factors in atrial fibrillation. J Am Coll Cardiol 66 (2015), 2899–2906.
23. 23 Menezes, A.R., Lavie, C.J., DiNicolantonio, J.J., et al. Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc 88 (2013), 394–409.
24. 24 De Vos, C.B., Breithardt, G., Camm, A.J., et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J 163 (2012), 887–893.
25. 25 Boriani, G., Laroche, C., Diemberger, I., et al. ‘Real-world’ management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry. Europace 18 (2016), 648–657.
26. 26 Camm, A.J., Lip, G.Y., De Caterina, R., et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the Management of Atrial Fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33 (2012), 2719–2747.
27. 27 Van Gelder, I.C., Groenveld, H.F., Crijns, H.J., et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362 (2010), 1363–1373.
28. 28 Andersen, M.J., Borlaug, B.A., Heart failure with preserved ejection fraction: current understandings and challenges. Curr Cardiol Rep, 16, 2014, 501.
29. 29 Khazanie, P., Liang, L., Qualls, L.G., et al. Outcomes of Medicare beneficiaries with heart failure and atrial fibrillation. J Am Coll Cardiol HF 2 (2014), 41–48.
30. 30 Gupta, D.K., Shah, A.M., Castagno, D., et al. Heart failure with preserved ejection fraction in African Americans: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol HF 1 (2013), 156–163.
31. 31 Seliger, S.L., de Lemos, J., Neeland, I.J., et al. Older adults, “malignant” left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure: CHS (Cardiovascular Health Study). J Am Coll Cardiol HF 3 (2015), 445–455.